ArticleJournal of cellular and molecular medicine2026
PGK1 Drives Glial Glycolytic Reprogramming to Mediate Isoflurane-Induced Cognitive Impairment in Aged Mice.
Article in Journal of cellular and molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Isoflurane-induced neuroinflammation triggers cognitive impairment in aged mice, but its underlying mechanism remains unclear. This study investigated the molecular mechanism by which isoflurane promotes glycolytic reprogramming to cause cognitive dysfunction in aged mice and identified potential therapeutic targets. 18-month-old mice were placed in an anaesthetic induction chamber containing 2% isoflurane (ISO) for 2 h to induce anaesthesia; this procedure was repeated daily for 5 days to establish a model of age-related cognitive impairment in mice. Behavioural studies in mice were conducted using the Y-Maze, contextual fear conditioning test (CFCT), Novel Object Recognition (NOR) test, and water maze test. Immunofluorescence analysis was employed to detect changes in the expression of microglia-related proteins PGK1, Hip, iNOS, Arg1, and P65. RT-PCR was employed to detect changes in mRNA expression levels of GLUT2, PKM2, HK2, and LDHA, which are associated with cellular metabolic reprogramming. ELISA was used to measure alterations in TNF-β, IL-4, IL-10, IL-6, IL-1β, and TNF-α cytokines. ISO enhanced glycolytic flux via PGK1, thereby driving microglia polarization toward the pro-inflammatory M1 phenotype and triggering neuroinflammation, ultimately leading to cognitive impairment in mice. Supplementing the glycolytic intermediate FBP reversed the anti-inflammatory effects induced by PGK1 knockdown, confirmed that PGK1 exerted its effects through the "PGK1-glycolysis axis." Mechanistically, PGK1 knockdown effectively suppressed M1 polarization of microglia while promoting their transition to the anti-inflammatory M2 phenotype. This significantly mitigated ISO-induced neuroinflammation and neuronal injury, ultimately improving cognitive function in mice. These findings reveal that PGK1 serves as a key molecular link between ISO anaesthesia and neuroinflammatory cognitive impairment. Targeting and inhibiting PGK1 exerts neuroprotective effects by reprogramming microglial glucose metabolism and phenotype, providing novel theoretical insights and potential therapeutic strategies for preventing ISO-induced neurological complications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.